



## Cassava Sciences to Present at H.C. Wainwright's 23rd Annual Global Investment Conference

September 9, 2021

AUSTIN, Texas, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, announced today that management will present at H.C. Wainwright's 23<sup>rd</sup> Annual Global Investment Conference, a virtual event that takes place September 13-15, 2021.

Cassava Sciences' presentation is a 'fireside chat' with Vernon T. Bernardino, PhD., Managing Director, Biotechnology Equity Research, at H.C. Wainwright.

Event details follow:

**Date:** Monday, September 13<sup>th</sup>

**Time:** 7:00 a.m. Eastern Time

**Webcast:** <https://www.CassavaSciences.com/company-presentations>

Cassava Sciences' fireside chat will be available for replay for 90 days following the conference on [www.CassavaSciences.com](http://www.CassavaSciences.com) in the 'Investors' section.

### About Alzheimer's Disease

Alzheimer's disease is a progressive brain disorder that destroys memory and thinking skills. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to over 150 million by 2050.<sup>1</sup> The annual global cost of dementia is now above \$1 trillion, according to *Alzheimer's Disease International*, a charitable organization.

### About Cassava Sciences, Inc.

Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.

Simufilam and SavaDx were both developed in-house. Cassava Sciences owns worldwide development and commercial rights to its research programs in Alzheimer's disease, and related technologies, without royalty obligations to any third party.

For more information, please visit <https://www.CassavaSciences.com>

### Contact Information:

Eric Schoen, Chief Financial Officer

Cassava Sciences, Inc.

[eschoen@CassavaSciences.com](mailto:eschoen@CassavaSciences.com)

(512) 501-2450

<sup>1</sup> *Alzheimer's Disease International, Dementia Statistics*, available on-line and accessed September 8, 2021.



Source: Cassava Sciences, Inc.